Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.79), in-line with the analyst estimate of ($0.79). Revenue for the quarter came in at $9.9 million versus the consensus estimate of $3.29 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.